- Home
- SILC vs LCTX Comparison
SILC vs LCTX Comparison
Compare SILC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- LCTX
- Stock Information
- Founded
- SILC 1987
- LCTX 1990
- Country
- SILC Israel
- LCTX United States
- Employees
- SILC N/A
- LCTX N/A
- Industry
- SILC Computer Manufacturing
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- LCTX Health Care
- Exchange
- SILC Nasdaq
- LCTX Nasdaq
- Market Cap
- SILC 84.7M
- LCTX 95.2M
- IPO Year
- SILC 1994
- LCTX N/A
- Fundamental
- Price
- SILC $15.29
- LCTX $0.49
- Analyst Decision
- SILC Hold
- LCTX Strong Buy
- Analyst Count
- SILC 2
- LCTX 5
- Target Price
- SILC N/A
- LCTX $4.20
- AVG Volume (30 Days)
- SILC 14.8K
- LCTX 860.2K
- Earning Date
- SILC 04-28-2025
- LCTX 05-13-2025
- Dividend Yield
- SILC N/A
- LCTX N/A
- EPS Growth
- SILC N/A
- LCTX N/A
- EPS
- SILC N/A
- LCTX N/A
- Revenue
- SILC $58,134,000.00
- LCTX $9,557,000.00
- Revenue This Year
- SILC $6.26
- LCTX N/A
- Revenue Next Year
- SILC $19.14
- LCTX $232.66
- P/E Ratio
- SILC N/A
- LCTX N/A
- Revenue Growth
- SILC N/A
- LCTX 19.42
- 52 Week Low
- SILC $11.35
- LCTX $0.37
- 52 Week High
- SILC $18.24
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- SILC 56.30
- LCTX 54.19
- Support Level
- SILC $14.99
- LCTX $0.45
- Resistance Level
- SILC $15.90
- LCTX $0.49
- Average True Range (ATR)
- SILC 0.59
- LCTX 0.03
- MACD
- SILC 0.11
- LCTX 0.00
- Stochastic Oscillator
- SILC 65.87
- LCTX 72.25
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.